Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.

MLA

Sharman, Jeff P., et al. “Obinutuzumab plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-Cell Lymphoma: The Phase II GATHER Study.” Leukemia & Lymphoma, vol. 60, no. 4, Apr. 2019, pp. 894–903. EBSCOhost, https://doi.org/10.1080/10428194.2018.1515940.

APA

Sharman, J. P., Forero-Torres, A., Costa, L. J., Flinn, I. W., Inhorn, L., Kelly, K., Bessudo, A., Fayad, L. E., Kaminski, M. S., Evens, A. M., Flowers, C. R., Sahin, D., Mundt, K. E., Sandmann, T., Fingerle-Rowson, G., Vignal, C., Mobasher, M., & Zelenetz, A. D. (2019). Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Leukemia & Lymphoma, 60(4), 894–903. https://doi.org/10.1080/10428194.2018.1515940

Chicago

Sharman, Jeff P., Andres Forero-Torres, Luciano J. Costa, Ian W. Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, et al. 2019. “Obinutuzumab plus CHOP Is Effective and Has a Tolerable Safety Profile in Previously Untreated, Advanced Diffuse Large B-Cell Lymphoma: The Phase II GATHER Study.” Leukemia & Lymphoma 60 (4): 894–903. doi:10.1080/10428194.2018.1515940.